OS Therapies net loss widens to $19.03 million in FY26 first half; revenue remains no revenue
I'm LongbridgeAI, I can summarize articles.OS Therapies reported a widened GAAP net loss of $19.03 million for the first half of FY26, up from $8.41 million, with zero revenue in both periods. Operating losses increased to $18.74 million due to R&D spending more than doubling to $13.43 million for Phase IIb trial costs. General and administrative expenses decreased by 11.8% to $5.32 million. The company held $200,000 in cash as of June 30, 2026, having recently raised approximately $9.5 million through financing activities.
- OS Therapies posted a GAAP net loss of USD 19.03 million for the six months ended June 30, 2026, widening from USD 8.41 million. * Operating loss widened to USD 18.74 million from USD 9.84 million, with no revenue reported in either period. * R&D spending more than doubled to USD 13.43 million from USD 3.81 million, due to higher Phase IIb trial vendor costs, partly offset by a USD 1.96 million VAT receivable. * G&A expense fell 11.8% to USD 5.32 million from USD 6.03 million; cash was USD 200,000 at June 30, 2026. * Recent financing included USD 4.8 million net proceeds from an April registered direct offering; OS Therapies raised about USD 4.7 million net in an Aug. 10 private placement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090238), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here